Abstract
Pancreatic cancer is one of the deadliest malignancies, costing the lives of more than 30,000 patients every year. It often presents in advanced stages not amenable to surgery. Gemcitabine is currently considered to be the standard of care for the treatment of advanced pancreatic cancer. Combination of gemcitabine with certain other cytotoxic drugs, including cisplatin, oxaliplatin, capecitabine, and 5-fluorouracil have been undertaken, but all have failed to provide substantial increases in survival benefit. However, neoadjuvant algorithms and targeted therapies, including combinations of gemcitabine with erlotinib suggest more promising results. New targeted therapies in combination with gemcitabine are currently in Phase II and III trials, possibly implicating a primary position for them in future treatment. In this paper we present an overview of the current treatment options for the different presenting stages of pancreatic cancer, including adjuvant, neoadjuvant, and targeted therapies, and attempt to provide a comprehensive analysis of the disparate research indicated on this front.
Keywords: Pancreatic adenocarcinoma, neoadjuvant therapy, adjuvant therapy, targeted therapies
Current Medicinal Chemistry
Title: Current Adjuvant and Targeted Therapies for Pancreatic Adenocarcinoma
Volume: 15 Issue: 17
Author(s): Sabrina E. Sanchez and Jose G. Trevino
Affiliation:
Keywords: Pancreatic adenocarcinoma, neoadjuvant therapy, adjuvant therapy, targeted therapies
Abstract: Pancreatic cancer is one of the deadliest malignancies, costing the lives of more than 30,000 patients every year. It often presents in advanced stages not amenable to surgery. Gemcitabine is currently considered to be the standard of care for the treatment of advanced pancreatic cancer. Combination of gemcitabine with certain other cytotoxic drugs, including cisplatin, oxaliplatin, capecitabine, and 5-fluorouracil have been undertaken, but all have failed to provide substantial increases in survival benefit. However, neoadjuvant algorithms and targeted therapies, including combinations of gemcitabine with erlotinib suggest more promising results. New targeted therapies in combination with gemcitabine are currently in Phase II and III trials, possibly implicating a primary position for them in future treatment. In this paper we present an overview of the current treatment options for the different presenting stages of pancreatic cancer, including adjuvant, neoadjuvant, and targeted therapies, and attempt to provide a comprehensive analysis of the disparate research indicated on this front.
Export Options
About this article
Cite this article as:
Sanchez E. Sabrina and Trevino G. Jose, Current Adjuvant and Targeted Therapies for Pancreatic Adenocarcinoma, Current Medicinal Chemistry 2008; 15 (17) . https://dx.doi.org/10.2174/092986708784872348
DOI https://dx.doi.org/10.2174/092986708784872348 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma
Current Molecular Pharmacology Chronopharmacology and Antimicrobial Therapeutics
Current Clinical Pharmacology In Silico Target Identification and Molecular Docking Studies of Natural Cytotoxic Compound Borivilianoside H
Current Biotechnology Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry Regulation of MicroRNAs in Inflammation-Associated Colorectal Cancer: A Mechanistic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Repositioning Through Network Pharmacology
Current Topics in Medicinal Chemistry Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma
Current Signal Transduction Therapy Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Current Concepts for the Combined Treatment Modality of Ionizing Radiation with Anticancer Agents
Current Pharmaceutical Design Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Metabolism of Dietary Flavonoids in Liver Microsomes
Current Drug Metabolism Subject index to volume 3
Current Cancer Drug Targets Novel Pharmacologic Approaches to the Prevention and Treatment of Ulcerative Colitis
Current Pharmaceutical Design The Antitumor Activity of a Novel Fluorobenzamidine against Dimethylhydrazine- Induced Colorectal Cancer in Rats
Anti-Cancer Agents in Medicinal Chemistry Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Cancer Antibody Enhanced Real Time Imaging Cell Probes – a Novel Theranostic Tool using Polymer Linked Carbon Nanotubes and Quantum Dots
Anti-Cancer Agents in Medicinal Chemistry The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance
Current Molecular Medicine Comparison of the Growth Curves of Cancer Cells and Cancer Stem Cells
Current Stem Cell Research & Therapy